| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dietetics | 8 | 2022 | 13 | 4.020 |
Why?
|
| Nutritionists | 7 | 2022 | 9 | 3.320 |
Why?
|
| Protein Processing, Post-Translational | 16 | 2021 | 284 | 3.020 |
Why?
|
| General Practitioners | 4 | 2022 | 10 | 2.520 |
Why?
|
| Acetylglucosamine | 6 | 2019 | 46 | 1.860 |
Why?
|
| Australia | 13 | 2022 | 235 | 1.620 |
Why?
|
| Proteome | 5 | 2021 | 87 | 1.320 |
Why?
|
| Proteomics | 8 | 2021 | 246 | 1.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2022 | 1085 | 1.240 |
Why?
|
| N-Acetylglucosaminyltransferases | 4 | 2015 | 18 | 1.220 |
Why?
|
| Primary Health Care | 9 | 2022 | 702 | 1.180 |
Why?
|
| Diet | 6 | 2022 | 513 | 1.130 |
Why?
|
| Life Style | 3 | 2022 | 338 | 1.050 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2020 | 139 | 1.020 |
Why?
|
| Patient-Centered Care | 3 | 2020 | 106 | 1.010 |
Why?
|
| Glycoproteins | 3 | 2015 | 238 | 0.960 |
Why?
|
| Osteoblasts | 2 | 2014 | 99 | 0.900 |
Why?
|
| State Medicine | 1 | 2022 | 7 | 0.870 |
Why?
|
| Humans | 57 | 2022 | 68525 | 0.830 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 7 | 0.830 |
Why?
|
| Home Care Services | 1 | 2022 | 84 | 0.830 |
Why?
|
| Nutritional Sciences | 1 | 2021 | 21 | 0.800 |
Why?
|
| General Practice | 1 | 2020 | 5 | 0.780 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 445 | 0.780 |
Why?
|
| Osteogenesis | 3 | 2023 | 152 | 0.750 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 86 | 0.740 |
Why?
|
| Cultural Diversity | 1 | 2020 | 67 | 0.730 |
Why?
|
| Research | 1 | 2021 | 214 | 0.730 |
Why?
|
| Antiviral Agents | 1 | 2021 | 211 | 0.690 |
Why?
|
| Polymers | 1 | 2020 | 244 | 0.670 |
Why?
|
| Health Education | 1 | 2021 | 279 | 0.670 |
Why?
|
| Health Behavior | 1 | 2022 | 458 | 0.660 |
Why?
|
| Nasal Polyps | 1 | 2020 | 184 | 0.650 |
Why?
|
| Exercise | 2 | 2022 | 657 | 0.640 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 301 | 0.630 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 8 | 2020 | 306 | 0.630 |
Why?
|
| Neoplasms | 5 | 2020 | 1660 | 0.630 |
Why?
|
| Qualitative Research | 5 | 2022 | 368 | 0.620 |
Why?
|
| Nanoparticles | 1 | 2020 | 254 | 0.610 |
Why?
|
| Insulin Receptor Substrate Proteins | 3 | 2016 | 18 | 0.570 |
Why?
|
| Lens, Crystalline | 3 | 2005 | 39 | 0.550 |
Why?
|
| Prediabetic State | 3 | 2021 | 48 | 0.550 |
Why?
|
| Liver | 1 | 2021 | 1118 | 0.540 |
Why?
|
| Glycosylation | 9 | 2023 | 185 | 0.530 |
Why?
|
| Rhinitis | 1 | 2020 | 383 | 0.530 |
Why?
|
| Bone Marrow Cells | 2 | 2023 | 217 | 0.520 |
Why?
|
| Epigenomics | 1 | 2015 | 29 | 0.510 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2014 | 10 | 0.510 |
Why?
|
| Food | 1 | 2015 | 52 | 0.510 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 94 | 0.510 |
Why?
|
| Eye Proteins | 3 | 2005 | 160 | 0.510 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 65 | 0.510 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 442 | 0.480 |
Why?
|
| Telemedicine | 1 | 2022 | 699 | 0.470 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 167 | 0.470 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 307 | 0.470 |
Why?
|
| Smoking Cessation | 1 | 2022 | 1032 | 0.460 |
Why?
|
| Acetylgalactosamine | 1 | 2013 | 10 | 0.460 |
Why?
|
| Animals | 27 | 2023 | 20877 | 0.450 |
Why?
|
| Signal Transduction | 7 | 2021 | 2688 | 0.450 |
Why?
|
| Models, Molecular | 1 | 2014 | 546 | 0.430 |
Why?
|
| Smoking | 1 | 2020 | 1449 | 0.420 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 370 | 0.400 |
Why?
|
| Nutrition Therapy | 2 | 2022 | 21 | 0.400 |
Why?
|
| Membrane Proteins | 4 | 2020 | 617 | 0.400 |
Why?
|
| Health Personnel | 3 | 2022 | 286 | 0.380 |
Why?
|
| Collagen | 4 | 2021 | 636 | 0.370 |
Why?
|
| Amino Acid Sequence | 7 | 2020 | 1082 | 0.370 |
Why?
|
| Chromatography, Liquid | 6 | 2020 | 120 | 0.370 |
Why?
|
| Models, Biological | 1 | 2014 | 981 | 0.370 |
Why?
|
| Glutathione | 4 | 2020 | 343 | 0.360 |
Why?
|
| Isoflavones | 2 | 2020 | 31 | 0.360 |
Why?
|
| src Homology Domains | 1 | 2009 | 29 | 0.360 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 1446 | 0.320 |
Why?
|
| Mice | 13 | 2023 | 8472 | 0.320 |
Why?
|
| Arginine | 2 | 2021 | 102 | 0.310 |
Why?
|
| Adult | 13 | 2022 | 21375 | 0.310 |
Why?
|
| Protein Biosynthesis | 2 | 2020 | 181 | 0.300 |
Why?
|
| Immunotherapy | 2 | 2020 | 212 | 0.290 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 595 | 0.290 |
Why?
|
| Aged | 8 | 2022 | 14842 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 2790 | 0.280 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 493 | 0.270 |
Why?
|
| Mitochondria | 3 | 2019 | 643 | 0.260 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2017 | 98 | 0.260 |
Why?
|
| Mass Spectrometry | 3 | 2013 | 284 | 0.260 |
Why?
|
| HEK293 Cells | 4 | 2021 | 326 | 0.260 |
Why?
|
| Phosphoproteins | 1 | 2005 | 202 | 0.250 |
Why?
|
| Nutritional Status | 2 | 2022 | 112 | 0.240 |
Why?
|
| Nucleus Accumbens | 2 | 2019 | 417 | 0.240 |
Why?
|
| Cellular Senescence | 1 | 2004 | 112 | 0.230 |
Why?
|
| Homes for the Aged | 1 | 2022 | 16 | 0.220 |
Why?
|
| Male | 16 | 2022 | 37281 | 0.220 |
Why?
|
| Rosaceae | 1 | 2022 | 1 | 0.220 |
Why?
|
| National Health Programs | 1 | 2022 | 11 | 0.220 |
Why?
|
| Phosphorylation | 5 | 2016 | 1199 | 0.220 |
Why?
|
| Female | 15 | 2022 | 38015 | 0.210 |
Why?
|
| Water | 1 | 2003 | 228 | 0.210 |
Why?
|
| Bone Marrow | 1 | 2023 | 168 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2022 | 1329 | 0.210 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 37 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2021 | 2 | 0.210 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 49 | 0.210 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 58 | 0.210 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2021 | 16 | 0.210 |
Why?
|
| Private Practice | 1 | 2021 | 19 | 0.210 |
Why?
|
| Telomere-Binding Proteins | 1 | 2021 | 2 | 0.210 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 499 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 27 | 0.200 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 14 | 0.200 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2016 | 67 | 0.200 |
Why?
|
| Queensland | 1 | 2021 | 1 | 0.200 |
Why?
|
| New South Wales | 1 | 2021 | 10 | 0.200 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 10 | 0.200 |
Why?
|
| Myocytes, Cardiac | 2 | 2017 | 442 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 135 | 0.200 |
Why?
|
| Maleates | 1 | 2020 | 7 | 0.200 |
Why?
|
| Styrene | 1 | 2020 | 5 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.200 |
Why?
|
| Lipid Bilayers | 1 | 2020 | 24 | 0.200 |
Why?
|
| Patient Advocacy | 1 | 2021 | 40 | 0.190 |
Why?
|
| Polystyrenes | 1 | 2020 | 20 | 0.190 |
Why?
|
| Hepacivirus | 1 | 2021 | 90 | 0.190 |
Why?
|
| Mucus | 1 | 2020 | 33 | 0.190 |
Why?
|
| Professional Role | 1 | 2021 | 80 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1172 | 0.190 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2020 | 9 | 0.190 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2020 | 10 | 0.190 |
Why?
|
| Asia | 1 | 2020 | 59 | 0.190 |
Why?
|
| Bortezomib | 1 | 2020 | 45 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2021 | 124 | 0.190 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2020 | 14 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 955 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2020 | 85 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 503 | 0.180 |
Why?
|
| Food Quality | 1 | 2019 | 4 | 0.180 |
Why?
|
| Peptide Fragments | 3 | 2013 | 483 | 0.180 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2019 | 16 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 92 | 0.180 |
Why?
|
| Smell | 1 | 2020 | 131 | 0.180 |
Why?
|
| Patient Care Team | 1 | 2022 | 311 | 0.180 |
Why?
|
| Methylation | 2 | 2021 | 56 | 0.180 |
Why?
|
| Biocatalysis | 2 | 2021 | 23 | 0.180 |
Why?
|
| Feeding and Eating Disorders | 1 | 2021 | 106 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 230 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 929 | 0.170 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 40 | 0.170 |
Why?
|
| Aortic Valve | 1 | 2021 | 249 | 0.170 |
Why?
|
| Thioredoxins | 1 | 2019 | 26 | 0.170 |
Why?
|
| STAT5 Transcription Factor | 1 | 2019 | 18 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 177 | 0.170 |
Why?
|
| Protein Conformation | 2 | 2014 | 362 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 331 | 0.170 |
Why?
|
| Lipids | 1 | 2020 | 298 | 0.170 |
Why?
|
| Serine | 3 | 2009 | 99 | 0.170 |
Why?
|
| Molecular Imaging | 1 | 2018 | 45 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 94 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 71 | 0.160 |
Why?
|
| Feeding Behavior | 1 | 2020 | 224 | 0.160 |
Why?
|
| Cell Lineage | 1 | 2019 | 146 | 0.160 |
Why?
|
| Actins | 1 | 2019 | 249 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 1849 | 0.160 |
Why?
|
| Body Weight | 1 | 2020 | 554 | 0.160 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 397 | 0.160 |
Why?
|
| Bacteriorhodopsins | 1 | 1998 | 47 | 0.160 |
Why?
|
| Family Practice | 1 | 2020 | 312 | 0.160 |
Why?
|
| Cell Line | 2 | 2014 | 1752 | 0.160 |
Why?
|
| Breast | 1 | 2018 | 137 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 403 | 0.160 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 24 | 0.160 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2018 | 53 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 265 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 114 | 0.150 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2017 | 19 | 0.150 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2017 | 19 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.150 |
Why?
|
| Aging | 1 | 2003 | 911 | 0.150 |
Why?
|
| Rhodopsin | 1 | 1998 | 135 | 0.150 |
Why?
|
| Protein Binding | 3 | 2021 | 1027 | 0.150 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 54 | 0.150 |
Why?
|
| Alcoholism | 2 | 2017 | 1109 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 65 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 199 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 700 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2020 | 597 | 0.150 |
Why?
|
| NAD | 1 | 2017 | 73 | 0.150 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2017 | 84 | 0.150 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 144 | 0.150 |
Why?
|
| Motor Neurons | 1 | 2017 | 98 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2020 | 866 | 0.140 |
Why?
|
| Hydroxylation | 3 | 2021 | 41 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1548 | 0.140 |
Why?
|
| Drug-Seeking Behavior | 1 | 2019 | 213 | 0.140 |
Why?
|
| Oxidation-Reduction | 4 | 2020 | 567 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2020 | 1341 | 0.140 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 21 | 0.140 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 14 | 0.140 |
Why?
|
| Thiazolidines | 1 | 2016 | 23 | 0.140 |
Why?
|
| Dendritic Cells | 1 | 2018 | 201 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1070 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 596 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 189 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 378 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 659 | 0.130 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Cell Line, Transformed | 1 | 2015 | 100 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2023 | 1034 | 0.130 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 184 | 0.130 |
Why?
|
| Post-Synaptic Density | 1 | 2015 | 7 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 87 | 0.130 |
Why?
|
| Middle Aged | 7 | 2022 | 21119 | 0.130 |
Why?
|
| Trypsin | 2 | 2005 | 64 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 290 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2798 | 0.130 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2014 | 7 | 0.130 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2014 | 16 | 0.130 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 117 | 0.130 |
Why?
|
| Dendritic Spines | 1 | 2015 | 76 | 0.120 |
Why?
|
| Synapses | 1 | 2017 | 222 | 0.120 |
Why?
|
| Aquaporins | 2 | 2004 | 8 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2014 | 57 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2005 | 204 | 0.120 |
Why?
|
| Protein Stability | 1 | 2014 | 89 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 2356 | 0.120 |
Why?
|
| Substrate Specificity | 1 | 2014 | 234 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2014 | 71 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 778 | 0.120 |
Why?
|
| Sequence Deletion | 2 | 2004 | 89 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 274 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2021 | 3702 | 0.120 |
Why?
|
| Genome, Human | 1 | 2013 | 62 | 0.120 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 226 | 0.120 |
Why?
|
| Protein Transport | 1 | 2014 | 280 | 0.120 |
Why?
|
| Central Nervous System Depressants | 1 | 2015 | 182 | 0.120 |
Why?
|
| Carbohydrate Conformation | 1 | 2013 | 25 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 308 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 214 | 0.110 |
Why?
|
| Chromatography, Affinity | 1 | 2013 | 73 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 282 | 0.110 |
Why?
|
| Astrocytes | 1 | 2015 | 270 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 163 | 0.110 |
Why?
|
| Rats | 3 | 2019 | 5300 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 138 | 0.110 |
Why?
|
| Apoptosis | 4 | 2022 | 1640 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 508 | 0.110 |
Why?
|
| Kallikreins | 1 | 2013 | 323 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2673 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 1032 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2013 | 176 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 639 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 742 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2019 | 718 | 0.090 |
Why?
|
| Proline | 2 | 2020 | 52 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2003 | 381 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1173 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2009 | 19 | 0.090 |
Why?
|
| Amino Acid Motifs | 1 | 2009 | 77 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2009 | 99 | 0.090 |
Why?
|
| Peptide Mapping | 2 | 2005 | 39 | 0.080 |
Why?
|
| Threonine | 2 | 2005 | 47 | 0.080 |
Why?
|
| Acetylation | 2 | 2021 | 94 | 0.080 |
Why?
|
| HeLa Cells | 2 | 2021 | 237 | 0.080 |
Why?
|
| Ethanol | 1 | 2015 | 892 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 222 | 0.080 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 301 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 211 | 0.080 |
Why?
|
| Binding Sites | 1 | 2009 | 631 | 0.080 |
Why?
|
| Proteins | 1 | 2011 | 473 | 0.080 |
Why?
|
| Glucose | 2 | 2006 | 307 | 0.080 |
Why?
|
| Adipocytes | 1 | 2006 | 88 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 331 | 0.070 |
Why?
|
| Disease Progression | 2 | 2020 | 1037 | 0.070 |
Why?
|
| Insulin | 2 | 2006 | 617 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2550 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2006 | 241 | 0.060 |
Why?
|
| Asparagine | 1 | 2004 | 15 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2004 | 144 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2003 | 49 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 434 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 95 | 0.060 |
Why?
|
| Xenopus laevis | 1 | 2003 | 60 | 0.060 |
Why?
|
| Oocytes | 1 | 2003 | 57 | 0.060 |
Why?
|
| Permeability | 1 | 2003 | 131 | 0.060 |
Why?
|
| Adipogenesis | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.060 |
Why?
|
| Amino Acids | 1 | 2003 | 131 | 0.060 |
Why?
|
| Mammals | 1 | 2023 | 47 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 420 | 0.050 |
Why?
|
| Systems Theory | 1 | 2022 | 13 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 57 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2018 | 1692 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2021 | 18 | 0.050 |
Why?
|
| Biotinylation | 1 | 2021 | 27 | 0.050 |
Why?
|
| Health Care Reform | 1 | 2022 | 62 | 0.050 |
Why?
|
| Cattle | 2 | 2005 | 475 | 0.050 |
Why?
|
| Sister Chromatid Exchange | 1 | 2021 | 7 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 99 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2021 | 36 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2021 | 63 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 69 | 0.050 |
Why?
|
| Mitosis | 1 | 2021 | 76 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 770 | 0.050 |
Why?
|
| Collagen Type VIII | 1 | 2020 | 7 | 0.050 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2020 | 9 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2020 | 21 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2077 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2021 | 294 | 0.050 |
Why?
|
| Self-Management | 1 | 2021 | 82 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2020 | 28 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 72 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2020 | 97 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2020 | 111 | 0.050 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 24 | 0.050 |
Why?
|
| Fibrillar Collagens | 1 | 2020 | 49 | 0.050 |
Why?
|
| Autophagy | 1 | 2022 | 207 | 0.050 |
Why?
|
| Self Report | 1 | 2022 | 370 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 38 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 93 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 53 | 0.050 |
Why?
|
| Autoantigens | 1 | 2020 | 91 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2020 | 87 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2020 | 147 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 265 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2021 | 523 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2020 | 175 | 0.040 |
Why?
|
| Prostate | 1 | 2020 | 116 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2020 | 66 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2022 | 297 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2021 | 791 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2019 | 16 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 18 | 0.040 |
Why?
|
| L-Selectin | 1 | 2019 | 28 | 0.040 |
Why?
|
| Self Tolerance | 1 | 2019 | 8 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 392 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 70 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 5708 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 56 | 0.040 |
Why?
|
| Breast Diseases | 1 | 2018 | 40 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 191 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 252 | 0.040 |
Why?
|
| Cyanogen Bromide | 1 | 1998 | 14 | 0.040 |
Why?
|
| Halobacterium salinarum | 1 | 1998 | 15 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 133 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 201 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2017 | 13 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2017 | 20 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2019 | 118 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2017 | 48 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2017 | 32 | 0.040 |
Why?
|
| Point Mutation | 1 | 1998 | 97 | 0.040 |
Why?
|
| Cysteine | 1 | 1998 | 112 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 419 | 0.040 |
Why?
|
| Conditioning, Operant | 1 | 2019 | 241 | 0.040 |
Why?
|
| Glutamine | 1 | 2017 | 45 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 47 | 0.040 |
Why?
|
| Ventricular Function | 1 | 2017 | 93 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 47 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2021 | 413 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2019 | 222 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 31 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2017 | 101 | 0.040 |
Why?
|
| Elastin | 1 | 2017 | 116 | 0.040 |
Why?
|
| Antioxidants | 1 | 2019 | 304 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 258 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 116 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2019 | 470 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 424 | 0.040 |
Why?
|
| Social Support | 1 | 2019 | 423 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2016 | 30 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 498 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 26 | 0.040 |
Why?
|
| Boronic Acids | 1 | 2016 | 40 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 223 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 514 | 0.030 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2015 | 16 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 946 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 138 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 455 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 238 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 96 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 304 | 0.030 |
Why?
|
| Cues | 1 | 2019 | 654 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2453 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 384 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 852 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.030 |
Why?
|
| Cocaine | 1 | 2019 | 555 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 3185 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 799 | 0.030 |
Why?
|
| Laboratories | 1 | 2013 | 44 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 2083 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2017 | 902 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2264 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2015 | 435 | 0.030 |
Why?
|
| Myocardium | 1 | 2017 | 1204 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1533 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 2011 | 53 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1593 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 2093 | 0.020 |
Why?
|
| Child | 1 | 2021 | 6400 | 0.020 |
Why?
|
| Neurons | 1 | 2015 | 881 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1293 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 4843 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 7264 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 8903 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2006 | 30 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 81 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2005 | 73 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 272 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2005 | 397 | 0.010 |
Why?
|